FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1594514919> ?p ?o ?g. }

• W1594514919 abstract "Background Prostate cancer is a common cancer in elderly men and in some will prove fatal. Standard treatments for localised disease include surgery ( radical prostatectomy), radiotherapy and active monitoring. New emerging therapies are being evaluated with the aim of reducing the complication rate associated with standard therapies, as well as developing an effective treatment. One such modality is cryotherapy, a procedure that introduces probes directly into the prostate tumour and kills the malignant cells by a freezing process. Objectives This review aims to evaluate the relative clinical and economic benefits of cryotherapy compared to standard therapies for the primary treatment of localised prostate cancer. Search methods Our search strategy included an electronic search of MEDLINE from 1996 to December 2006, plus EMBASE (Exerpta Medica Database), the Cochrane library, ISI Science Citation Index, Database of Abstracts and Reviews of Effectiveness (DARE), and LILACS to identify all relevant published randomised trials of cryotherapy for localised prostate cancer. Cancerlit→ and HealthSTAR databases were searched to their final date. Handsearching of relevant journals was undertaken. Selection criteria Only published randomised trials comparing the effectiveness of cryotherapy with radical prostatectomy, radiotherapy or active monitoring for the primary treatment of men with localised prostate cancer were eligible for inclusion in this review. Data collection and analysis Data were extracted from eligible studies, and included study design, participants, interventions and outcomes. Primary outcome measures were biochemical disease‐free survival, disease‐free survival and treatment‐induced complications. Secondary outcomes included disease‐specific survival, overall survival, quality‐of‐life outcome measures and economic impact measures. Main results There were no randomised trials found comparing cryotherapy with other therapies for the primary treatment of localised prostate cancer. All studies identified were case series. To indicate the level of the available evidence, studies that evaluated cryotherapy as a primary therapy, using transrectal ultrasound guidance and urethral warming in at least 50 patients with localised prostate cancer, and a minimum of one year follow up, were reviewed. Eight case series were identified that complied with these criteria; two were retrospective. The patients recruited (n = 1483) had an age range from 41 to 84 years, stages T1 = 0 to 43%, T2 = 24 to 88%, T3 = 1 to 41%, and T4 = 0 to 14%. The mean preoperative PSA level ranged from 9.7 to 39 ng/mL, with Gleason scores < 7 and ranging from 6 to 37%. One additional study that compared cryotherapy (total cryotherapy and standard cryotherapy with urethral preservation) with radical prostatectomy was also identified and reviewed. In this study the success rates, defined as a post‐treatment PSA of 0.2 ng/mL or less, were reported as 96% for total cryotherapy, 49% for standard cryotherapy and 73% for radical prostatectomy. Four studies did not monitor the temperature of the cyroprocedure and reported 17 to 28% of patients had a positive biopsy following cryotherapy with a mean PSA nadir of 0.55 to 1.75 ng/mL (median 0.4 to 1.85 ng/mL). The other four studies used thermocouples to monitor the temperature of the cryo‐procedure and reported progression‐free survival rates of 71 to 89% with 1.4 to 13% of patients having a positive biopsy post‐cryotherapy. At 5 years, overall survival was reported as 89 to 92% in two studies, and disease‐specific survival as 94% in one study. The major complications observed in all studies included impotence (47 to 100%), incontinence (1.3 to 19%), and urethral sloughing (3.9 to 85%), with less common complications of fistula (0 to 2%), bladder‐neck obstruction (2 to 55%), stricture (2.2 to 17%) and pain (0.4 to 3.1%). Most patients were sent home the following day (range 1 to 4 days). Authors' conclusions Cryotherapy offers a potential alternative to standard therapies for the primary treatment of localised prostate cancer. However, the poor quality of the available studies makes it difficult to determine the relative benefits of this modality. Randomised trials are needed to fully evaluate the full potential of cryotherapy in men with this disease. Patients selecting cryotherapy as their therapeutic option should be made fully aware of the reported efficacy, complications and the low‐grade evidence from which these data are derived." @default.
• W1594514919 created "2016-06-24" @default.
• W1594514919 creator A5014903338 @default.
• W1594514919 creator A5018944921 @default.
• W1594514919 creator A5032518609 @default.
• W1594514919 creator A5043350291 @default.
• W1594514919 date "2007-07-18" @default.
• W1594514919 modified "2023-09-27" @default.
• W1594514919 title "Cryotherapy for localised prostate cancer" @default.
• W1594514919 cites W1490833936 @default.
• W1594514919 cites W1989739561 @default.
• W1594514919 cites W1995359568 @default.
• W1594514919 cites W2019095051 @default.
• W1594514919 cites W2021021529 @default.
• W1594514919 cites W2021084304 @default.
• W1594514919 cites W2023851593 @default.
• W1594514919 cites W2036592418 @default.
• W1594514919 cites W2041940347 @default.
• W1594514919 cites W2054307343 @default.
• W1594514919 cites W2057434007 @default.
• W1594514919 cites W2070638378 @default.
• W1594514919 cites W2071693341 @default.
• W1594514919 cites W2071970547 @default.
• W1594514919 cites W2072713635 @default.
• W1594514919 cites W2081211881 @default.
• W1594514919 cites W2081782488 @default.
• W1594514919 cites W2109188829 @default.
• W1594514919 cites W2109694492 @default.
• W1594514919 cites W2131058209 @default.
• W1594514919 cites W2154861747 @default.
• W1594514919 cites W2160537008 @default.
• W1594514919 cites W2412503643 @default.
• W1594514919 cites W2414460600 @default.
• W1594514919 cites W2462870609 @default.
• W1594514919 cites W4317528128 @default.
• W1594514919 doi "https://doi.org/10.1002/14651858.cd005010.pub2" @default.
• W1594514919 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17636783" @default.
• W1594514919 hasPublicationYear "2007" @default.
• W1594514919 type Work @default.
• W1594514919 sameAs 1594514919 @default.
• W1594514919 citedByCount "36" @default.
• W1594514919 countsByYear W15945149192012 @default.
• W1594514919 countsByYear W15945149192013 @default.
• W1594514919 countsByYear W15945149192014 @default.
• W1594514919 countsByYear W15945149192018 @default.
• W1594514919 countsByYear W15945149192021 @default.
• W1594514919 countsByYear W15945149192022 @default.
• W1594514919 crossrefType "journal-article" @default.
• W1594514919 hasAuthorship W1594514919A5014903338 @default.
• W1594514919 hasAuthorship W1594514919A5018944921 @default.
• W1594514919 hasAuthorship W1594514919A5032518609 @default.
• W1594514919 hasAuthorship W1594514919A5043350291 @default.
• W1594514919 hasConcept C121608353 @default.
• W1594514919 hasConcept C126322002 @default.
• W1594514919 hasConcept C141071460 @default.
• W1594514919 hasConcept C143998085 @default.
• W1594514919 hasConcept C17744445 @default.
• W1594514919 hasConcept C199539241 @default.
• W1594514919 hasConcept C2776478404 @default.
• W1594514919 hasConcept C2779134260 @default.
• W1594514919 hasConcept C2779466945 @default.
• W1594514919 hasConcept C2779473830 @default.
• W1594514919 hasConcept C2780149145 @default.
• W1594514919 hasConcept C2780192828 @default.
• W1594514919 hasConcept C509974204 @default.
• W1594514919 hasConcept C71924100 @default.
• W1594514919 hasConcept C95190672 @default.
• W1594514919 hasConceptScore W1594514919C121608353 @default.
• W1594514919 hasConceptScore W1594514919C126322002 @default.
• W1594514919 hasConceptScore W1594514919C141071460 @default.
• W1594514919 hasConceptScore W1594514919C143998085 @default.
• W1594514919 hasConceptScore W1594514919C17744445 @default.
• W1594514919 hasConceptScore W1594514919C199539241 @default.
• W1594514919 hasConceptScore W1594514919C2776478404 @default.
• W1594514919 hasConceptScore W1594514919C2779134260 @default.
• W1594514919 hasConceptScore W1594514919C2779466945 @default.
• W1594514919 hasConceptScore W1594514919C2779473830 @default.
• W1594514919 hasConceptScore W1594514919C2780149145 @default.
• W1594514919 hasConceptScore W1594514919C2780192828 @default.
• W1594514919 hasConceptScore W1594514919C509974204 @default.
• W1594514919 hasConceptScore W1594514919C71924100 @default.
• W1594514919 hasConceptScore W1594514919C95190672 @default.
• W1594514919 hasLocation W15945149191 @default.
• W1594514919 hasLocation W15945149192 @default.
• W1594514919 hasOpenAccess W1594514919 @default.
• W1594514919 hasPrimaryLocation W15945149191 @default.
• W1594514919 hasRelatedWork W1854522109 @default.
• W1594514919 hasRelatedWork W1963775361 @default.
• W1594514919 hasRelatedWork W2015338340 @default.
• W1594514919 hasRelatedWork W2175808153 @default.
• W1594514919 hasRelatedWork W2271751063 @default.
• W1594514919 hasRelatedWork W2545489389 @default.
• W1594514919 hasRelatedWork W2940700295 @default.
• W1594514919 hasRelatedWork W4246083279 @default.
• W1594514919 hasRelatedWork W71823916 @default.
• W1594514919 hasRelatedWork W193188344 @default.
• W1594514919 isParatext "false" @default.
• W1594514919 isRetracted "false" @default.
• W1594514919 magId "1594514919" @default.
• W1594514919 workType "article" @default.